HOUSE CONCURRENT RESOLUTION NO. 3001

(By Mr. Speaker, Mr. Kiss, and Delegate Trump )

(By Request of the Executive)



Authorizing the adoption and implementation of the use or reference of the Federal Supply Schedule ("FSS") to establish a benchmark for prescription drug prices for the negotiation and purchase of brand name drugs by the State of West Virginia; and further, authorizing the West Virginia Pharmaceutical Cost Management Council to implement the strategic plan established in the Reference Pricing Report submitted on September 10, 2004, to the Joint Committee on Government and Finance in accordance with the provisions of article three-c, chapter five-a, et seq; and further the Legislature requests the Council to recommend legislative enactments as necessary from time to time to implement the same.

Whereas, In accordance with the provisions of subsection (d), section six, article three-c, chapter five-a of the code of West Virginia, 1931, as amended, the West Virginia Pharmaceutical Cost Management Council has recommended the establishment of a pricing schedule using or referencing FSS pricing as a benchmark for prescription drug prices for the negotiation and purchase of brand name drugs; and
Whereas, In accordance with the provisions of subsection (e), section six, article three-c, chapter five-a of the code of West Virginia, 1931, as amended, the adoption of a concurrent resolution by the Legislature is required to authorize the implementation of the FSS reference pricing schedule as a benchmark for prescription drug prices for the negotiation and purchase of brand name drugs and the strategic plan; therefore, be it
Resolved by the Legislature of West Virginia:
That the Legislature hereby adopts the use or reference of the FSS to establish a benchmark for prescription drug prices for the negotiation and purchase of brand name drugs by the state of West Virginia; and the Legislature authorizes the West Virginia Pharmaceutical Cost Management Council to implement the FSS pricing schedule as a benchmark for the negotiation and purchase of brand name drugs and the strategic plan established in the Reference Pricing Report submitted September 10, 2004, all in accordance with the provisions of article three-c, chapter five-a, et seq; and further the Legislature requests the Council to recommend legislative enactments as necessary from time to time to implement the same.